PP2A7 Antibody
Description
PP2A Antibody Classification and Target Specificity
PP2A antibodies generally target either:
-
Structural subunits (Aα/β regulatory subunits)
-
Catalytic subunits (Cα/β isoforms)
-
Post-translational modifications (e.g., phosphorylation at Tyr307)
Regulatory Role in Disease Pathogenesis
-
Alzheimer’s Disease: Phosphorylation at Y307 inactivates PP2A, correlating with tau hyperphosphorylation. Antibodies like F-8 detect this modification in AD brain tissues and APP/PS1 transgenic mice .
-
Autoimmunity: PP2A constrains T-cell differentiation and S1P-mediated lymphocyte egress, with FTY720 (an S1P analog) showing therapeutic potential in multiple sclerosis .
Technical Limitations in Phosphorylation Studies
-
Earlier "anti-pY307" antibodies exhibited cross-reactivity with non-target phosphosites (Y127/Y284), as shown by mass spectrometry . Newer antibodies (e.g., pY127/Y284-specific) resolve this issue .
Mechanistic Studies
-
PP2A dephosphorylates:
Therapeutic Target Validation
-
PP2A inactivation via Y307 phosphorylation exacerbates neurofibrillary tangle formation in AD models .
-
PP2A modulators show promise in cancer and autoimmune therapies .
Methodological Considerations
-
Western Blotting: Use 10% SDS-PAGE and PVDF membranes for optimal detection of PP2A-Cα (~36 kDa) .
-
Immunohistochemistry: Aberrant PP2A-Y307 phosphorylation localizes to hippocampal neurons with neurofibrillary tangles .
Emerging Controversies
Product Specs
Composition: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Q&A
Based on analysis of current research on P2X7 receptor antibodies (note: "PP2A7" appears to be a nomenclature error; corrected to P2X7 based on context), here are structured FAQs addressing key research considerations:
Advanced Research Challenges
How to resolve contradictory data on P2X7 antibody binding dynamics?
Conflicting reports often arise from:
-
Conformational sensitivity: Antibodies like E155 lose binding within seconds of ATP exposure due to receptor shedding .
-
Post-translational modifications: Phosphorylation at Thr304 or methylation at Leu309 alters epitope accessibility (parallel findings from PP2Ac studies) .
Solution: Combine time-resolved flow cytometry (pre/post ATP treatment) with phospho/methylation-site mutagenesis to isolate confounding variables .
What in vivo models best assess therapeutic efficacy of anti-P2X7 antibodies?
The humanized NSG mouse GVHD model provides robust data:
Methodological Considerations
How to address cross-reactivity in P2X7 antibody batches?
-
Epitope mapping: Clone L4 targets human-specific extracellular domains (aa 200-280), avoiding conserved regions shared with murine P2X7 .
-
Lot testing: Include species cross-reactivity panels using:
